Individualized Growth Hormone Dosing Aims to Maintain Normal Growth Velocity in Children After Catch-Up Growth

Children with growth hormone deficiency (GHD) often undergo GH replacement therapy to achieve normal growth. While initial catch-up growth is a common and desired outcome, maintaining a consistent, normal growth velocity in the long term, especially after this initial rapid phase, presents a significant clinical challenge. Current standard-of-care often involves fixed or weight-based dosing regimens that may not fully account for individual variability in response or the changing needs of a child as they age and their growth dynamics evolve. This can lead to suboptimal growth outcomes, potential overtreatment, or undertreatment, highlighting a critical gap in personalized therapeutic strategies for sustained growth. The need for individualized dosing aims to optimize growth hormone (GH) efficacy and safety, ensuring children continue to grow appropriately without excessive or insufficient hormonal stimulation.

This study aimed to investigate the feasibility and efficacy of an individualized Growth Hormone (GH) dosing strategy. Researchers sought to determine if adapting the GH dosage could effectively maintain a normal growth velocity in prepubertal children. The target population included children who had already demonstrated a positive response to initial GH treatment, achieving what was defined as "fulfilled catch-up growth" (where the difference to their target height was less than -0.6 SDS). The core objective was to explore whether a dynamic adjustment of GH dosage, rather than a static regimen, could sustain optimal growth rates after the initial period of rapid catch-up, thereby addressing the challenge of long-term growth management in these patients. The abstract, however, does not specify the number of participants, the duration of the intervention, the exact dosing protocols, or the methods used for dose adaptation.

The provided abstract does not contain any specific results, numerical data, statistical analyses, or quantitative findings from the study. Consequently, it is not possible to report on the efficacy, safety, or specific outcomes of the individualized growth hormone dosing strategy as investigated by the researchers. The abstract primarily outlines the objective of the study without presenting any data to support conclusions or demonstrate the impact of the proposed intervention. Therefore, no concrete findings, percentages, p-values, or fold-changes can be extracted or reported from the available information.